Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting

Journal of Infection

Volumn 55, Issue 5, 2007, Pages 464-469

  Manosuthi, Weerawat ^a   Chaovavanich, Achara ^a   Tansuphaswadikul, Somsit ^a   Prasithsirikul, Wisit ^a   Inthong, Yoawarat ^a   Chottanapund, Suthat ^a   Sittibusaya, Chayanan ^a   Moolasart, Visal ^a   Termvises, Patamavadee ^a   Sungkanuparph, Somnuek ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; HIV; Immune reconstitution; Incidence; Opportunistic infections; Risk factors; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; MACROLIDE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CRYPTOCOCCOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROBABILITY; RETINITIS; RETROSPECTIVE STUDY; RISK FACTOR; TUBERCULOSIS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS RETINITIS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; THAILAND; TUBERCULOSIS;

EID: 35348971860     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.07.002     Document Type: Article

References (26)

1. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 315 7117 (1997) 1194-1199
2. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353 9156 (1999) 863-868
3. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 13 (1998) 853-860
4. Lawn S.D., Bekker L.G., and Miller R.F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5 6 (2005) 361-373
5. Shelburne III S.A., Hamill R.J., Rodriguez-Barradas M.C., Greenberg S.B., Atmar R.L., Musher D.W., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81 3 (2002) 213-227
6. Braitstein P., Brinkhof M.W., Dabis F., Schechter M., Boulle A., Miotti P., et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 9513 (2006) 817-824
7. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282 23 (1999) 2220-2226
8. Michelet C., Arvieux C., Francois C., Besnier J.M., Rogez J.P., Breux J.P., et al. Opportunistic infections occurring during highly active antiretroviral treatment. Aids 12 14 (1998) 1815-1822
9. Sungkanuparph S., Vibhagool A., Mootsikapun P., Chetchotisakd P., Tansuphaswaswadikul S., and Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. Aids 17 14 (2003) 2129-2131
10. Ambrus Sr. J.L., and Ambrus Jr. J.L. Nutrition and infectious diseases in developing countries and problems of acquired immunodeficiency syndrome. Exp Biol Med (Maywood) 229 6 (2004) 464-472
11. Schaible U.E., and Kaufmann S.H. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med 4 5 (2007) e115
12. Bates I., Fenton C., Gruber J., Lalloo D., Medina Lara A., Squire S.B., et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis 4 5 (2004) 267-277
13. Silveira J.M., Sassi R.A., de Oliveira Netto I.C., and Hetzel J.L. Prevalence of and factors related to tuberculosis in seropositive human immunodeficiency virus patients at a reference center for treatment of human immunodeficiency virus in the southern region of the state of Rio Grande do Sul. Brazil. J Bras Pneumol 32 1 (2006) 48-55
14. Ruxrungtham K., and Phanuphak P. Update on HIV/AIDS in Thailand. J Med Assoc Thai 84 Suppl. 1 (2001) S1-S17
15. Lipman M., and Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 19 1 (2006) 20-25
16. Badri M., Ehrlich R., Wood R., Pulerwitz T., and Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 5 3 (2001) 225-232
17. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 9 (2003) 1009-1021
18. Whalen C.C., Nsubuga P., Okwera A., Johnson J.L., Hom D.L., Michael N.L., et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 14 9 (2000) 1219-1228
19. Badri M., Wilson D., and Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359 9323 (2002) 2059-2064
20. Santoro-Lopes G., de Pinho A.M., Harrison L.H., and Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 34 4 (2002) 543-546
21. Carcelain G., Debre P., and Autran B. Reconstitution of CD4 + T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 13 4 (2001) 483-488
22. Lederman M.M. Immune restoration and CD4 + T-cell function with antiretroviral therapies. Aids 15 Suppl. 2 (2001) S11-S15
23. Jon F. Tuberculosis. 2nd ed. (2004), Mosby, Spain
24. Calmy A., Pinoges L., Szumilin E., Zachariah R., Ford N., and Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. Aids 20 8 (2006) 1163-1169
25. 3 in a resource-limited setting: efficacy and tolerability. Int J STD AIDS 16 3 (2005) 243-246
26. Zhou J., and Kumarasamy N. Predicting short-term disease progression among HIV-infected patients in Asia and the Pacific region: preliminary results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 6 3 (2005) 216-223